Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Immix Biopharma, Inc. (IMMX)
USD10.33
-0.36 (-3.32%)
US NASDAQ Healthcare Biotechnology
Address
11400 West Olympic Boulevard 90064
Los Angeles, CA, US
Los Angeles, CA, US
CEO
Ilya Rachman
Website
immixbio.com
IPO
2021-12-16
CIK 1873835 ISIN US45258H1068
Description
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD10.33
-0.36 (-3.32%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.11
Float Shares
40.34M
Free Float %
74.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.46% | +4.00% | +15.12% | +43.47% | +186.56% | +103.82% | +410.05% | +400.47% | +190.46% | +190.46% | +190.46% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
10.33
Low
14.00
+35.6%
Consensus
14.50
+40.4%
Median
14.50
+40.4%
High
15.00
+45.3%
DCF (Unlevered)
2.82
-72.7%
DCF (Levered)
2.82
-72.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
15.00
+45.3%
|
| Last Year | 3 |
13.67
+32.4%
|
| All Time | 4 |
12.00
+16.2%
|
Quality scores
Altman Z-Score
26.39
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-17.1% Q1'26: -20.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +835.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+16.6% Q1'26: +28.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.04× Q1'26: -0.02× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 2 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 1.00M (-100.0%)
|
—
est: 7.00M (-100.0%)
|
12.14M
8.58M – 15.59M
+73.4% YoY
|
56.42M
39.87M – 72.44M
+364.7% YoY
|
205.51M
205.51M – 205.51M
+264.3% YoY
|
332.06M
234.65M – 426.36M
+61.6% YoY
|
481.57M
340.31M – 618.34M
+45.0% YoY
|
| EBITDA |
-22.56M
|
-26.85M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-22.67M
|
-27.21M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-21.61M
est: -20.90M (-3.4%)
|
-29.44M
est: -21.72M (-35.5%)
|
-25.88M
-27.97M – -23.79M
-19.1% YoY
|
-23.84M
-32.84M – -14.84M
+7.9% YoY
|
-7.76M
-10.69M – -3.38M
+67.5% YoY
|
14.01M
8.67M – 19.18M
+280.6% YoY
|
60.00M
37.12M – 82.15M
+328.2% YoY
|
| SGA |
11.38M
|
13.70M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.76
est: -0.80 (+4.4%)
|
-0.89
est: -0.66 (-34.2%)
|
-0.77
-0.85 – -0.72
-16.1% YoY
|
-0.73
-1.00 – -0.45
+5.6% YoY
|
-0.21
-0.32 – -0.10
+70.7% YoY
|
0.43
0.26 – 0.58
+299.2% YoY
|
1.82
1.13 – 2.49
+328.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-13.48M
OE per share TTM
-0.46
Owner's Yield
-2.51%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
-3.1%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
8
Total invested
4.76M
Insider transactions (90d)
0
Beneficial owners (>5%)
9
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | GKCC, LLC | 3.26M | 19.99% | — | 3.26M | — | 10.00 | PN | United States of America | 2023-08-30 | ↗ |
| 2 | Yekaterina Chudnovsky | 3.26M | 19.99% | 3.26M | — | 3.26M | 10.00 | IN | United States of America | 2023-08-30 | ↗ |
| 3 | 27-4413262 | 1.46M | 5.80% | 1.46M | — | 1.46M | — | OO | Maryland | 2024-02-07 | ↗ |
| 4 | Identification Nos. of above persons (. | 1.46M | 5.80% | 1.46M | — | 1.46M | — | IN | States | 2024-02-07 | ↗ |
| 5 | Marc Bistricer | 695.6K | 5.28% | — | 695.6K | — | 695.6K | HC | Canada | 2022-02-09 | ↗ |
| 6 | Murchinson Ltd. | 695.6K | 5.28% | — | 695.6K | — | 695.6K | OO | Canada | 2022-02-09 | ↗ |
| 7 | Altium Capital Management, LP | 122.4K | 1.60% | — | 122.4K | — | — | IA, PN | Delaware, United States of America | 2022-02-11 | ↗ |
| 8 | Altium Growth Fund, LP | 122.4K | 1.60% | — | 122.4K | — | — | PN | Delaware, United States of America | 2022-02-11 | ↗ |
| 9 | Altium Growth GP, LLC | 122.4K | 1.60% | — | 122.4K | — | — | OO | Delaware, United States of America | 2022-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
8
-61 vs prev Q
New positions
2
Closed positions
61
Increased
5
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 230.4K +230.4K (+100.0%) | 1.21B +1.2B (+100.0%) | 0.72% +0.722 pp | 1.17% +1.166 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 2 | JANUS HENDERSON GROUP PLC | 3.92M +3.9M (+100.0%) | 20.47M +20.5M (+100.0%) | 12.28% +12.283 pp | 0.01% +0.009 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 3 | SATURN V CAPITAL MANAGEMENT LLC | 3.00M +3.0M (+100.0%) | 15.69M +15.7M (+100.0%) | 9.39% +9.394 pp | 2.88% +2.879 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 4 | EVENTIDE ASSET MANAGEMENT, LLC | 2.55M +2.5M (+100.0%) | 13.33M +13.3M (+100.0%) | 7.98% +7.984 pp | 0.21% +0.208 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 5 | MARSHALL WACE, LLP | 1.98M +1.9M (+3,495.4%) | 10.35M +10.2M (+8,897.3%) | 6.20% +6.014 pp | 0.01% +0.009 pp | USD5.14 +1.8% | 2 qtrs — |
| 6 | MILLENNIUM MANAGEMENT LLC | 1.66M +1.7M (+100.0%) | 8.68M +8.7M (+100.0%) | 5.20% +5.199 pp | 0.00% +0.004 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 7 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.50M +1.5M (+100.0%) | 7.85M +7.8M (+100.0%) | 4.70% +4.698 pp | 0.01% +0.012 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 8 | VANGUARD GROUP INC | 1.10M +365.7K (+50.1%) | 5.73M +4.2M (+275.6%) | 3.43% +0.997 pp | 0.00% +0.000 pp | USD3.54 +47.7% | 15 qtrs — |
| 9 | LOGOS GLOBAL MANAGEMENT LP | 1.00M +1.0M (+100.0%) | 5.23M +5.2M (+100.0%) | 3.13% +3.132 pp | 0.32% +0.316 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 10 | BLEICHROEDER LP | 1.00M +150.0K (+17.6%) | 5.23M +3.5M (+194.4%) | 3.13% +0.297 pp | 0.92% +0.574 pp | USD3.27 +59.9% | 8 qtrs — |
| 11 | BLUE OWL CAPITAL HOLDINGS LP | 986.2K +986.2K (+100.0%) | 5.16M +5.2M (+100.0%) | 3.09% +3.089 pp | 0.39% +0.386 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 12 | FRANKLIN RESOURCES INC | 980.4K +980.4K (+100.0%) | 5.13M +5.1M (+100.0%) | 3.07% +3.071 pp | 0.00% +0.001 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 13 | AMERIPRISE FINANCIAL INC | 452.1K +452.1K (+100.0%) | 2.36M +2.4M (+100.0%) | 1.42% +1.416 pp | 0.00% +0.001 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 14 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 393.9K +303.0K (+333.5%) | 2.06M +1.9M (+984.8%) | 1.23% +0.931 pp | 0.00% +0.000 pp | USD4.45 +17.5% | 4 qtrs — |
| 15 | PERCEPTIVE ADVISORS LLC | 338.9K +338.9K (+100.0%) | 1.77M +1.8M (+100.0%) | 1.06% +1.062 pp | 0.03% +0.032 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 16 | BURKEHILL GLOBAL MANAGEMENT, LP | 294.1K +294.1K (+100.0%) | 1.54M +1.5M (+100.0%) | 0.92% +0.921 pp | 0.10% +0.101 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 17 | RENAISSANCE TECHNOLOGIES LLC | 258.6K +237.1K (+1,102.8%) | 1.35M +1.3M (+2,909.9%) | 0.81% +0.738 pp | 0.00% +0.002 pp | USD4.97 +5.2% | 2 qtrs — |
| 18 | GEODE CAPITAL MANAGEMENT, LLC | 246.1K +58.6K (+31.2%) | 1.29M +895.6K (+228.6%) | 0.77% +0.145 pp | 0.00% +0.000 pp | USD3.32 +57.5% | 15 qtrs — |
| 19 | GOLDMAN SACHS GROUP INC | 208.4K +208.4K (+100.0%) | 1.09M +1.1M (+100.0%) | 0.65% +0.653 pp | 0.00% +0.000 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 20 | JANE STREET GROUP, LLC | 167.1K +152.2K (+1,016.4%) | 874.1K +842.8K (+2,693.8%) | 0.52% +0.474 pp | 0.00% +0.000 pp | USD4.95 +5.7% | 2 qtrs — |
| 21 | BLACKROCK, INC. | 130.3K +87.2K (+202.4%) | 681.2K +591.2K (+656.8%) | 0.41% +0.264 pp | 0.00% +0.000 pp | USD4.13 +26.6% | 6 qtrs — |
| 22 | MORGAN STANLEY | 126.6K +6.0K (+4.9%) | 662.2K +410.0K (+162.6%) | 0.40% -0.006 pp | 0.00% +0.000 pp | USD2.88 +81.6% | 10 qtrs — |
| 23 | LGT FUND MANAGEMENT CO LTD. | 125.0K +125.0K (+100.0%) | 660.0K +660.0K (+100.0%) | 0.39% +0.392 pp | 0.05% +0.052 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 24 | EAM INVESTORS, LLC | 120.9K +120.9K (+100.0%) | 632.1K +632.1K (+100.0%) | 0.38% +0.379 pp | 0.07% +0.070 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 25 | J. GOLDMAN & CO LP | 118.3K +118.3K (+100.0%) | 618.5K +618.5K (+100.0%) | 0.37% +0.370 pp | 0.02% +0.016 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 26 | NORTHERN TRUST CORP | 100.7K +11.4K (+12.7%) | 526.4K +339.8K (+182.1%) | 0.32% +0.017 pp | 0.00% +0.000 pp | USD3.44 +52.0% | 9 qtrs — |
| 27 | BANK OF NEW YORK MELLON CORP | 98.7K +98.7K (+100.0%) | 516.4K +516.4K (+100.0%) | 0.31% +0.309 pp | 0.00% +0.000 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 28 | LONGAEVA PARTNERS L.P. | 98.0K +98.0K (+100.0%) | 512.7K +512.7K (+100.0%) | 0.31% +0.307 pp | 0.04% +0.043 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 29 | STATE STREET CORP | 97.4K -1.6K (-1.6%) | 509.2K +302.4K (+146.2%) | 0.30% -0.025 pp | 0.00% +0.000 pp | USD2.26 +131.4% | 15 qtrs — |
| 30 | CITADEL ADVISORS LLC | 75.3K -14.5K (-16.1%) | 394.0K +206.3K (+109.9%) | 0.24% -0.064 pp | 0.00% +0.000 pp | USD2.09 +150.2% | 2 qtrs — |
| 31 | OMERS ADMINISTRATION CORP | 74.7K +74.7K (+100.0%) | 390.7K +390.7K (+100.0%) | 0.23% +0.234 pp | 0.00% +0.003 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 32 | VIRTU FINANCIAL LLC | 73.8K +73.8K (+100.0%) | 386.0K +386.0K (+100.0%) | 0.23% +0.231 pp | 0.02% +0.015 pp | USD5.23 +0.0% | 3 qtrs — |
| 33 | SEI INVESTMENTS CO | 73.6K +73.6K (+100.0%) | 384.8K +384.8K (+100.0%) | 0.23% +0.230 pp | 0.00% +0.000 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 34 | UNITED CAPITAL FINANCIAL ADVISERS, LLC | 70.7K +— (+0.0%) | 369.7K +221.9K (+150.2%) | 0.22% -0.014 pp | 0.00% +0.001 pp | USD2.09 +150.2% | 2 qtrs — |
| 35 | TOCQUEVILLE ASSET MANAGEMENT L.P. | 68.6K +28.3K (+70.3%) | 358.5K +274.4K (+326.2%) | 0.21% +0.081 pp | 0.01% +0.004 pp | USD4.04 +29.5% | 10 qtrs — |
| 36 | UBS GROUP AG | 58.6K +56.7K (+2,920.6%) | 306.5K +302.4K (+7,457.9%) | 0.18% +0.177 pp | 0.00% +0.000 pp | USD5.14 +1.8% | 9 qtrs — |
| 37 | ADAR1 CAPITAL MANAGEMENT, LLC | 50.0K +50.0K (+100.0%) | 261.5K +261.5K (+100.0%) | 0.16% +0.157 pp | 0.02% +0.019 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 38 | QUBE RESEARCH & TECHNOLOGIES LTD | 49.8K +49.8K (+100.0%) | 260.5K +260.5K (+100.0%) | 0.16% +0.156 pp | 0.00% +0.000 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 39 | XTX TOPCO LTD | 46.4K +11.2K (+32.0%) | 242.6K +169.2K (+230.3%) | 0.15% +0.028 pp | 0.01% +0.003 pp | USD2.85 +83.5% | 4 qtrs — |
| 40 | CIBC PRIVATE WEALTH GROUP, LLC | 40.0K +30.0K (+300.0%) | 209.2K +188.3K (+901.0%) | 0.13% +0.092 pp | 0.00% +0.000 pp | USD4.45 +17.5% | 2 qtrs — |
| 41 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | 35.0K +— (+0.0%) | 183.1K +109.9K (+150.2%) | 0.11% -0.007 pp | 0.11% +0.038 pp | USD2.08 +151.4% | 3 qtrs — |
| 42 | BARCLAYS PLC | 35.0K +35.0K (+100.0%) | 183.1K +183.1K (+100.0%) | 0.11% +0.110 pp | 0.00% +0.000 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 43 | JUMP FINANCIAL, LLC | 33.8K +33.8K (+100.0%) | 176.8K +176.8K (+100.0%) | 0.11% +0.106 pp | 0.00% +0.002 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 44 | HUDSON BAY CAPITAL MANAGEMENT LP | 33.6K +33.6K (+100.0%) | 176.0K +176.0K (+100.0%) | 0.11% +0.105 pp | 0.00% +0.001 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 45 | PERSISTENT ASSET PARTNERS LTD | 31.8K +31.8K (+100.0%) | 166.1K +166.1K (+100.0%) | 0.10% +0.100 pp | 0.07% +0.075 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 46 | PRIVATE ADVISOR GROUP, LLC | 31.7K +500.0 (+1.6%) | 165.9K +100.7K (+154.2%) | 0.10% -0.005 pp | 0.00% +0.001 pp | USD6.89 -24.1% | 9 qtrs — |
| 47 | CONCURRENT INVESTMENT ADVISORS, LLC | 27.4K +27.4K (+100.0%) | 143.5K +143.5K (+100.0%) | 0.09% +0.086 pp | 0.00% +0.002 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 48 | QUADRATURE CAPITAL LTD | 22.1K +22.1K (+100.0%) | 115.7K +115.7K (+100.0%) | 0.07% +0.069 pp | 0.00% +0.001 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 49 | SQUAREPOINT OPS LLC | 21.5K +21.5K (+100.0%) | 112.4K +112.4K (+100.0%) | 0.07% +0.067 pp | 0.00% +0.000 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 50 | IMPRINT WEALTH LLC | 20.0K -47.4K (-70.3%) | 104.6K -36.3K (-25.7%) | 0.06% -0.162 pp | 0.49% +0.038 pp | USD2.09 +150.2% | 2 qtrs — |
| 51 | KERA CAPITAL PARTNERS, INC. | 13.0K +13.0K (+100.0%) | 75.8K +75.8K (+100.0%) | 0.04% +0.041 pp | 0.01% +0.009 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 52 | BALYASNY ASSET MANAGEMENT L.P. | 12.9K +12.9K (+100.0%) | 67.2K +67.2K (+100.0%) | 0.04% +0.040 pp | 0.00% +0.000 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 53 | COMMONWEALTH EQUITY SERVICES, LLC | 12.4K -3.7K (-22.8%) | 64.8K +30.8K (+90.4%) | 0.04% -0.015 pp | 0.00% +0.000 pp | USD2.92 +79.1% | 8 qtrs — |
| 54 | TOWER RESEARCH CAPITAL LLC (TRC) | 12.2K +12.2K (+100.0%) | 63.6K +63.6K (+100.0%) | 0.04% +0.038 pp | 0.00% +0.002 pp | USD5.23 +0.0% | 13 qtrs — |
| 55 | MATHES COMPANY, INC. | 10.7K +10.7K (+100.0%) | 56.0K +56.0K (+100.0%) | 0.03% +0.033 pp | 0.02% +0.020 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 56 | LIGHTHOUSE INVESTMENT PARTNERS, LLC | 10.0K +10.0K (+100.0%) | 52.4K +52.4K (+100.0%) | 0.03% +0.031 pp | 0.00% +0.002 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 57 | SBI SECURITIES CO., LTD. | 10.0K -7.5K (-42.9%) | 52.3K +15.7K (+43.0%) | 0.03% -0.027 pp | 0.00% +0.000 pp | USD2.20 +137.7% | 5 qtrs — |
| 58 | SNOWDEN CAPITAL ADVISORS LLC | 10.0K +— (+0.0%) | 52.3K +31.4K (+150.2%) | 0.03% -0.002 pp | 0.00% +0.001 pp | USD2.09 +150.2% | 2 qtrs — |
| 59 | ALLWORTH FINANCIAL LP | 5.7K +5.7K (+100.0%) | 29.9K +29.9K (+100.0%) | 0.02% +0.018 pp | 0.00% +0.000 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 60 | JPMORGAN CHASE & CO | 5.1K +5.1K (+100.0%) | 26.7K +26.7K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.000 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 61 | BNP PARIBAS ARBITRAGE, SNC | 2.7K +2.7K (+100.0%) | 14.1K +14.1K (+100.0%) | 0.01% +0.009 pp | 0.00% +0.000 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 62 | CITIGROUP INC | 2.0K +1.9K (+5,534.3%) | 10.3K +10.2K (+14,028.8%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD5.17 +1.2% | 2 qtrs — |
| 63 | CWM, LLC | 1.0K +1.0K (+100.0%) | 5.0K +5.0K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD5.23 +0.0% | 1 qtrs NEW |
| 64 | ROYAL BANK OF CANADA | 995.00 +995.0 (+100.0%) | 5.0K +5.0K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD5.23 +0.0% | 6 qtrs — |
| 65 | BANK OF AMERICA CORP /DE/ | 16.00 +4.0 (+33.3%) | 84.00 +59.0 (+236.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.75 +90.2% | 9 qtrs — |
| 66 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 3.00 -77.0 (-96.3%) | 16.00 -151.0 (-90.4%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.67 +213.2% | 4 qtrs — |
| 67 | MAI CAPITAL MANAGEMENT | — -2.0K (-100.0%) | — -4.2K (-100.0%) | 0.00% -0.007 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 68 | TRITONPOINT WEALTH, LLC | — -24.5K (-100.0%) | — -51.3K (-100.0%) | 0.00% -0.082 pp | 0.00% -0.004 pp | USD— | 3 qtrs SOLD |
| 69 | SRS CAPITAL ADVISORS, INC. | — -34.0 (-100.0%) | — -71.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 70 | COLONY GROUP, LLC | — -11.9K (-100.0%) | — -24.9K (-100.0%) | 0.00% -0.040 pp | 0.00% +0.000 pp | USD— | 7 qtrs SOLD |
| 71 | WELLS FARGO & COMPANY/MN | — -330.0 (-100.0%) | — -690.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 13 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 52 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.81% | 465.8K | 0.65% |
| 2 | Global X - S&P Biotech ETF CURE.AX | 0.22% | 78.0K | 0.45% |
| 3 | State Street SPDR S&P Biotech ETF XBI | 0.22% | 23.44M | 0.35% |
| 4 | iShares Micro-Cap ETF IWC | 0.10% | 1.53M | 0.60% |
| 5 | T. Rowe Price Innovation Leaders ETF TNXT | 0.08% | 13.9K | 0.49% |
| 6 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.04% | 468.7K | 0.20% |
| 7 | Pacer WealthShield ETF PWS | 0.04% | 10.9K | 0.60% |
| 8 | iShares Russell 2000 Growth ETF IWO | 0.03% | 4.13M | 0.24% |
| 9 | Direxion Daily S&P Biotech Bull 3X Shares LABU | 0.03% | 182.1K | 0.96% |
| 10 | State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc) R2US.L | 0.02% | 977.8K | 0.30% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
4.00
Bullish
Ratio by volume
3.00
Bullish
Buys
4
Sells
1
Shares acquired
197.2K
Shares disposed
60.0K
Cash buys
2.00
Cash sales
—
Net activity
+137,159
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-10 | Rachman Ilya M | Director / Officer | P-Purchase | A | Common Stock | 746 | 6.67 | 5.0K | 1,141,683 | D | ↗ |
| 2025-12-10 | Morris Gabriel S | Director / Officer | P-Purchase | A | Common Stock | 770 | 6.58 | 5.1K | 291,429 | D | ↗ |
| 2025-12-08 | Morris Gabriel S | Director / Officer | X-InTheMoney | A | Common Stock | 156,000 | 0.80 | 124.8K | 426,844 | I | ↗ |
| 2025-11-21 | CHANG NANCY T | Director | A-Award | A | Stock Option (Right to Buy) | 39,643 | 4.33 | 171.7K | 39,643 | D | ↗ |
| 2025-09-17 | Rachman Ilya M | Director / Officer | P-Purchase | A | Common Stock | 2,500 | 2.02 | 5.1K | 1,140,937 | D | ↗ |
| 2025-09-16 | Morris Gabriel S | Director / Officer | P-Purchase | A | Common Stock | 2,600 | 1.97 | 5.1K | 290,659 | D | ↗ |
| 2025-09-08 | CHANG NANCY T | Director | — | — | Common Stock | 0 | 0.00 | — | 496,940 | I | ↗ |
| 2025-06-20 | Rachman Ilya M | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 340,000 | 2.24 | 761.6K | 340,000 | D | ↗ |
| 2025-06-20 | Ng Carey | Director | A-Award | A | Stock Option (Right to Buy) | 33,000 | 2.24 | 73.9K | 33,000 | D | ↗ |
| 2025-06-20 | Morris Gabriel S | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 340,000 | 2.24 | 761.6K | 340,000 | D | ↗ |
| 2025-06-20 | Marquet Magda | Director | A-Award | A | Stock Option (Right to Buy) | 33,000 | 2.24 | 73.9K | 33,000 | D | ↗ |
| 2025-06-20 | Hsu Jason | Director | A-Award | A | Stock Option (Right to Buy) | 33,000 | 2.24 | 73.9K | 33,000 | D | ↗ |
| 2025-06-20 | Chudnovsky Yekaterina | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 33,000 | 2.24 | 73.9K | 33,000 | D | ↗ |
| 2025-06-20 | BUCHAN JANE | Director | A-Award | A | Stock Option (Right to Buy) | 33,000 | 2.24 | 73.9K | 33,000 | D | ↗ |
| 2025-06-20 | Adams Helen C. | Director | A-Award | A | Stock Option (Right to Buy) | 33,000 | 2.24 | 73.9K | 33,000 | D | ↗ |
| 2025-06-18 | Rachman Ilya M | Director / Officer | P-Purchase | A | Common Stock | 2,178 | 2.30 | 5.0K | 1,138,437 | D | ↗ |
| 2025-06-18 | Morris Gabriel S | Director / Officer | P-Purchase | A | Common Stock | 2,225 | 2.28 | 5.1K | 288,059 | D | ↗ |
| 2024-12-23 | Hsu Jason | Director | P-Purchase | A | Common Stock | 40,000 | 2.19 | 87.7K | 893,000 | D | ↗ |
| 2024-12-20 | Hsu Jason | Director | P-Purchase | A | Common Stock | 7,700 | 2.17 | 16.7K | 853,000 | D | ↗ |
| 2024-08-22 | Hsu Jason | Director | P-Purchase | A | Common Stock | 8,100 | 2.25 | 18.2K | 845,300 | — | ↗ |
| 2024-08-21 | Hsu Jason | Director | P-Purchase | A | Common Stock | 15,000 | 2.23 | 33.4K | 837,200 | — | ↗ |
| 2024-08-16 | Ng Carey | Director | P-Purchase | A | Common Stock | 10,000 | 1.86 | 18.6K | 20,000 | — | ↗ |
| 2024-07-24 | Hsu Jason | Director | P-Purchase | A | Common Stock | 6,000 | 2.15 | 12.9K | 822,200 | — | ↗ |
| 2024-07-18 | Hsu Jason | Director | P-Purchase | A | Common Stock | 3,200 | 2.07 | 6.6K | 816,200 | — | ↗ |
| 2024-06-11 | Rachman Ilya M | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 340,000 | 2.04 | 693.6K | 340,000 | — | ↗ |
| 2024-06-11 | Ng Carey | Director | A-Award | A | Stock Option (Right to Buy) | 33,000 | 2.04 | 67.3K | 33,000 | — | ↗ |
| 2024-06-11 | Morris Gabriel S | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 340,000 | 2.04 | 693.6K | 340,000 | — | ↗ |
| 2024-06-11 | Marquet Magda | Director | A-Award | A | Stock Option (Right to Buy) | 33,000 | 2.04 | 67.3K | 33,000 | — | ↗ |
| 2024-06-11 | Hsu Jason | Director | A-Award | A | Stock Option (Right to Buy) | 33,000 | 2.04 | 67.3K | 33,000 | — | ↗ |
| 2024-06-11 | Chudnovsky Yekaterina | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 33,000 | 2.04 | 67.3K | 33,000 | — | ↗ |
| 2024-06-11 | BUCHAN JANE | Director | A-Award | A | Stock Option (Right to Buy) | 33,000 | 2.04 | 67.3K | 33,000 | — | ↗ |
| 2024-06-11 | Adams Helen C. | Director | A-Award | A | Stock Option (Right to Buy) | 33,000 | 2.04 | 67.3K | 33,000 | — | ↗ |
| 2024-06-07 | Rachman Ilya M | Director / Officer | P-Purchase | A | Common Stock | 2,600 | 2.13 | 5.5K | 1,136,259 | — | ↗ |
| 2024-06-07 | Morris Gabriel S | Director / Officer | P-Purchase | A | Common Stock | 2,500 | 2.12 | 5.3K | 285,834 | — | ↗ |
| 2024-06-04 | Rachman Ilya M | Director / Officer | P-Purchase | A | Common Stock | 3,300 | 1.81 | 6.0K | 1,133,659 | — | ↗ |
| 2024-06-04 | Morris Gabriel S | Director / Officer | P-Purchase | A | Common Stock | 3,300 | 1.81 | 6.0K | 283,334 | — | ↗ |
| 2024-05-20 | Rachman Ilya M | Director / Officer | A-Award | A | Common Stock | 218,359 | 0.00 | — | 1,130,359 | — | ↗ |
| 2024-05-20 | Morris Gabriel S | Director / Officer | A-Award | A | Common Stock | 24,141 | 0.00 | — | 24,141 | — | ↗ |
| 2024-05-20 | Marquet Magda | Director | A-Award | A | Common Stock | 21,155 | 0.00 | — | 46,092 | — | ↗ |
| 2024-05-20 | BUCHAN JANE | Director | A-Award | A | Common Stock | 1,127 | 0.00 | — | 22,455 | — | ↗ |
| 2024-05-20 | Adams Helen C. | Director | A-Award | A | Common Stock | 74,241 | 0.00 | — | 174,754 | — | ↗ |
| 2024-05-15 | Ng Carey | Director | A-Award | A | Stock Option (Right to Buy) | 25,512 | 2.47 | 63.0K | 25,512 | — | ↗ |
| 2024-05-15 | Marquet Magda | Director | A-Award | A | Common Stock | 25,002 | 0.00 | — | 25,002 | — | ↗ |
| 2024-05-15 | Hsu Jason | Director | A-Award | A | Stock Option (Right to Buy) | 21,587 | 2.47 | 53.3K | 21,587 | — | ↗ |
| 2024-05-15 | BUCHAN JANE | Director | A-Award | A | Stock Option (Right to Buy) | 24,153 | 2.47 | 59.7K | 24,153 | — | ↗ |
| 2024-05-15 | Adams Helen C. | Director | A-Award | A | Common Stock | 87,740 | 0.00 | — | 100,740 | — | ↗ |
| 2024-05-14 | Rachman Ilya M | Director / Officer | P-Purchase | A | Common Stock | 4,300 | 2.25 | 9.7K | 912,000 | — | ↗ |
| 2024-05-14 | Morris Gabriel S | Director / Officer | P-Purchase | A | Common Stock | 4,500 | 2.23 | 10.0K | 85,816 | — | ↗ |
| 2023-12-11 | Hsu Jason | Director | P-Purchase | A | Common Stock | 31,000 | 4.67 | 144.9K | 813,000 | — | ↗ |
| 2023-12-08 | Hsu Jason | Director | P-Purchase | A | Common Stock | 25,000 | 4.88 | 122.0K | 782,000 | — | ↗ |
| 2023-09-15 | Hsu Jason | Director | P-Purchase | A | Common Stock | 7,000 | 2.49 | 17.4K | 757,000 | — | ↗ |
| 2023-09-14 | Ng Carey | Director | P-Purchase | A | Common Stock | 10,000 | 2.58 | 25.8K | 10,000 | — | ↗ |
| 2023-09-14 | Hsu Jason | Director | P-Purchase | A | Common Stock | 10,000 | 2.58 | 25.8K | 750,000 | — | ↗ |
| 2023-09-12 | Hsu Jason | Director | P-Purchase | A | Common Stock | 30,000 | 2.83 | 84.9K | 740,000 | — | ↗ |
| 2023-09-12 | Adams Helen C. | Director | P-Purchase | A | Common Stock | 13,000 | 2.96 | 38.5K | 13,000 | — | ↗ |
| 2023-09-11 | Hsu Jason | Director | P-Purchase | A | Common Stock | 25,000 | 2.89 | 72.3K | 710,000 | — | ↗ |
| 2023-09-08 | Hsu Jason | Director | P-Purchase | A | Common Stock | 10,000 | 2.53 | 25.3K | 685,000 | — | ↗ |
| 2023-09-07 | BUCHAN MELISSA JANE | Director | P-Purchase | A | Common Stock | 20,000 | 2.46 | 49.2K | 20,000 | — | ↗ |
| 2023-09-06 | Marquet Magda | Director | P-Purchase | A | Common Stock | 9,000 | 2.47 | 22.2K | 20,000 | — | ↗ |
| 2023-09-05 | Marquet Magda | Director | P-Purchase | A | Common Stock | 10,000 | 2.47 | 24.7K | 11,000 | — | ↗ |
| 2023-08-31 | Marquet Magda | Director | P-Purchase | A | Common Stock | 1,000 | 2.01 | 2.0K | 1,000 | — | ↗ |
| 2023-08-22 | Chudnovsky Yekaterina | Director / 10% Owner | — | I | Pre-Funded Common Stock Purchase Warrant | 1,913,661 | 0.00 | 191.37 | 0 | — | ↗ |
| 2023-08-14 | Rachman Ilya M | Director / Officer | A-Award | A | Stock Options | 293,000 | 1.86 | 545.0K | 293,000 | — | ↗ |
| 2023-08-14 | Morris Gabriel S | Director / Officer | A-Award | A | Stock Options | 293,000 | 1.86 | 545.0K | 293,000 | — | ↗ |
| 2023-08-11 | Rachman Ilya M | Director / Officer | A-Award | A | Stock Options | 193,000 | 1.86 | 359.0K | 193,000 | — | ↗ |
| 2023-08-11 | Ng Carey | Director | A-Award | A | Stock Options | 20,000 | 1.86 | 37.2K | 20,000 | — | ↗ |
| 2023-08-11 | Morris Gabriel S | Director / Officer | A-Award | A | Stock Options | 193,000 | 1.86 | 359.0K | 193,000 | — | ↗ |
| 2023-08-11 | Marquet Magda | Director | A-Award | A | Stock Options | 20,000 | 1.86 | 37.2K | 20,000 | — | ↗ |
| 2023-08-11 | Hsu Jason | Director | A-Award | A | Stock Options | 20,000 | 1.86 | 37.2K | 20,000 | — | ↗ |
| 2023-08-11 | BUCHAN MELISSA JANE | Director | A-Award | A | Stock Options | 20,000 | 1.86 | 37.2K | 20,000 | — | ↗ |
| 2023-08-11 | Adams Helen C. | Director | A-Award | A | Stock Options | 20,000 | 1.86 | 37.2K | 20,000 | — | ↗ |
| 2022-11-14 | Rachman Ilya M | Officer | P-Purchase | A | Common Stock | 150 | 0.99 | 148.50 | 907,700 | — | ↗ |
| 2022-11-14 | Morris Gabriel S | Officer | P-Purchase | A | Common Stock | 5,200 | 0.94 | 4.9K | 81,316 | — | ↗ |
| 2022-07-14 | Senn Sean | — | S-Sale | D | Common Stock | 200 | 2.75 | 550.00 | 899,800 | — | ↗ |
| 2022-07-14 | Rachman Ilya M | Officer | A-Award | A | Stock Options | 250,000 | 0.00 | — | 520,000 | — | ↗ |
| 2022-07-14 | Ng Carey | Director | A-Award | A | Stock Options | 16,000 | 0.00 | — | 16,000 | — | ↗ |
| 2022-07-14 | Morris Gabriel S | Officer | A-Award | A | Stock Options | 250,000 | 0.00 | — | 716,500 | — | ↗ |
| 2022-07-14 | Marquet Magda | Director | A-Award | A | Stock Options | 16,000 | 0.00 | — | 76,000 | — | ↗ |
| 2022-07-14 | Hsu Jason | Director | A-Award | A | Stock Options | 16,000 | 0.00 | — | 16,000 | — | ↗ |
| 2022-07-14 | BUCHAN MELISSA JANE | Director | A-Award | A | Stock Options | 16,000 | 0.00 | — | 46,000 | — | ↗ |
| 2022-07-14 | Adams Helen C. | Director | A-Award | A | Stock Options | 16,000 | 0.00 | — | 53,500 | — | ↗ |
| 2021-12-20 | Torchilin Vladimir P | Officer | P-Purchase | A | Common Stock | 3,000 | 5.00 | 15.0K | 905,200 | — | ↗ |
| 2021-12-20 | Rachman Ilya M | Director / Officer | P-Purchase | A | Common Stock | 2,500 | 5.00 | 12.5K | 902,500 | — | ↗ |
| 2021-12-20 | Ng Carey | Director | C-Conversion | D | Convertible Note | 0 | 0.85 | — | 0 | — | ↗ |
| 2021-12-20 | Morris Gabriel S | Director / Officer | C-Conversion | A | Common Stock | 123,176 | 0.85 | 104.7K | 246,703 | — | ↗ |
| 2021-12-20 | Hsu Jason | Director | C-Conversion | D | Convertible Note | 0 | 0.85 | — | 0 | — | ↗ |
| 2021-12-17 | Torchilin Vladimir P | Officer | P-Purchase | A | Common Stock | 2,200 | 4.47 | 9.8K | 902,200 | — | ↗ |
| 2021-12-15 | Torchilin Vladimir P | Officer | — | D | Common stock | 0 | 0.00 | — | 900,000 | — | ↗ |
| 2021-12-15 | Senn Sean | 10% Owner | — | D | Common stock | 0 | 0.00 | — | 900,000 | — | ↗ |
| 2021-12-15 | Ross Graham | Officer | — | D | Options (right to purchase) | 15,000 | 1.86 | 27.9K | 0 | — | ↗ |
| 2021-12-15 | Rachman Ilya M | Director / Officer | — | D | Options (right to purchase) | 270,000 | 1.86 | 502.2K | 0 | — | ↗ |
| 2021-12-15 | Ng Carey | Director | — | D | Convertible Note | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-15 | Morris Gabriel S | Director / Officer | — | D | Options (right to purchase) | 210,000 | 1.86 | 390.6K | 0 | — | ↗ |
| 2021-12-15 | Marquet Magda | Director | — | D | Options (right to purchase) | 60,000 | 1.86 | 111.6K | 0 | — | ↗ |
| 2021-12-15 | Hsu Jason | Director | — | I | Convertible Note | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-15 | BUCHAN MELISSA JANE | Director | — | D | Options (right to purchase) | 30,000 | 1.86 | 55.8K | 0 | — | ↗ |
| 2021-12-15 | Adams Helen C. | Director | — | D | Options (right to purchase) | 37,500 | 1.86 | 69.8K | 0 | — | ↗ |
| 2021-04-02 | Morris Gabriel S | Director / Officer | — | I | Warrants (right to purchase) | 60,000 | 0.80 | 48.0K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
54.41M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Gabriel Morris, Chief Financial Officer | 475.0K | — | — | 592.9K | 285.0K | — | 1.35M | 43.82% | ↗ |
| 2 | 2025 | Ilya Rachman, Chief Executive Officer | 475.0K | — | — | 592.9K | 285.0K | — | 1.35M | 43.82% | ↗ |
| 3 | 2024 | Ilya Rachman, Chief Executive Officer | 475.0K | — | — | 554.7K | 237.5K | — | 1.27M | 43.77% | ↗ |
| 4 | 2024 | Gabriel Morris, Chief Financial Officer | 475.0K | — | — | 554.7K | 237.5K | — | 1.27M | 43.77% | ↗ |
| 5 | 2024 | Graham Ross , Chief Medical Officer | 88.6K | — | — | — | — | — | 88.6K | 0.00% | ↗ |
| 6 | 2023 | Gabriel Morris, Chief Financial Officer | 446.0K | — | — | 460.9K | 223.0K | — | 1.13M | 40.79% | ↗ |
| 7 | 2023 | Ilya Rachman, Chief Executive Officer | 446.0K | — | — | 460.9K | 223.0K | — | 1.13M | 40.79% | ↗ |
| 8 | 2023 | Graham Ross , Chief Medical Officer | 104.4K | — | — | — | 52.2K | — | 156.6K | 0.00% | ↗ |
| 9 | 2022 | Ilya Rachman, Chief Executive Officer | 425.0K | — | 1.14M | 582.9K | 212.5K | — | 2.36M | 72.94% | ↗ |
| 10 | 2022 | Gabriel Morris, Chief Financial Officer | 425.0K | — | 1.14M | 582.9K | 212.5K | — | 2.36M | 72.94% | ↗ |
| 11 | 2021 | Gabriel Morris, Chief Financial Officer | 100.0K | — | — | 362.1K | — | — | 462.1K | 78.36% | ↗ |
| 12 | 2021 | Ilya Rachman, Chief Executive Officer | 193.3K | — | — | 203.4K | — | — | 396.7K | 51.27% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ilya Rachman | Co-Founder, CEO, Chief Scientific Officer & Chairman | 760.0K | — |
| Gabriel Morris | President, CFO & Director | 760.0K | male |
| Graham Ross FFPM | Chief Medical Officer & Head of Clinical Development | 88.6K | — |
| Sean Senn | Co-Founder | — | male |
| David Marks | Chief Medical Officer of Cell Therapy | — | — |
| Vladimir Torchilin | Scientific Co-Founder | — | — |
| Mel Davis-Pickett | Head of CMC Technical Development | — | male |
| Michael A. Grabow | Chief Commercial Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IMMX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
